Vanguard Fiduciary Trust’s Apimeds Pharmaceuticals US APUS Stock Holding History

Vanguard Fiduciary Trust’s Portfolio APUS Stock Details APUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.6K	Hold	2,404	–	–	﹤0.01%	3987
2026 Q1	$43K	Buy	+2,404	New	+$38.7K	﹤0.01%	3852

Other funds holding APUS

HTHT

Hemenway Trust Hemenway Trust Salem, New Hampshire $1.43B AUM 37.14% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Vanguard Fiduciary Trust's APUS Position: Q2 2026 in Review

Vanguard Fiduciary Trust held its Apimeds Pharmaceuticals US (APUS) position steady in Q2 2026 at 2,404 shares worth $21.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3987.

Vanguard Fiduciary Trust first reported a position in APUS in Q1 2026 and has held it in 2 quarters since. The position peaked at $43K in Q1 2026. 7 funds tracked by Wall St. Rank hold APUS as of Q2 2026.

Vanguard Fiduciary Trust held 2,404 shares of Apimeds Pharmaceuticals US worth $21.6K as of Q2 2026.
Vanguard Fiduciary Trust left its Apimeds Pharmaceuticals US share count unchanged in Q2 2026.
Apimeds Pharmaceuticals US made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3987 holding.
Vanguard Fiduciary Trust first reported a position in Apimeds Pharmaceuticals US in Q1 2026 and has held it in 2 quarters since.
Vanguard Fiduciary Trust's Apimeds Pharmaceuticals US position peaked at $43K in Q1 2026.
7 funds tracked by Wall St. Rank held Apimeds Pharmaceuticals US as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.